Lineage Cell Therapeutics
LCTX
LCTX
124 hedge funds and large institutions have $182M invested in Lineage Cell Therapeutics in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 39 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
1.15% less ownership
Funds ownership: 45.28% → 44.13% (-1.2%)
5% less capital invested
Capital invested by funds: $192M → $182M (-$9.95M)
31% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 39
Holders
124
Holding in Top 10
3
Calls
$1.61M
Puts
$289K
Top Buyers
| 1 | +$3.57M | |
| 2 | +$1.1M | |
| 3 | +$988K | |
| 4 |
Millennium Management
New York
|
+$768K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$747K |
Top Sellers
| 1 | -$8.29M | |
| 2 | -$2.29M | |
| 3 | -$1.02M | |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$913K |
| 5 |
Rafferty Asset Management
New York
|
-$488K |